Literature DB >> 11198499

Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.

T R Johnson1, J D Tobias.   

Abstract

Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system. In addition to their effects on spasticity, certain adverse cardiorespiratory effects have been reported. Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked. The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity. The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11198499     DOI: 10.1177/088307380001501211

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  3 in total

1.  Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment.

Authors:  Herbert R Henney; Michael Chez
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

2.  Tizanidine-induced acute severe cystitis in a female taking famotidine.

Authors:  Resham Raj Poudel; Nisha Kusum Kafle
Journal:  Clin Pharmacol       Date:  2015-07-29

3.  Limitations and obstacles of the spontaneous adverse drugs reactions reporting: Two "challenging" case reports.

Authors:  Caterina Palleria; Christian Leporini; Serafina Chimirri; Giuseppina Marrazzo; Sabrina Sacchetta; Lucrezia Bruno; Rosaria M Lista; Orietta Staltari; Antonio Scuteri; Francesca Scicchitano; Emilio Russo
Journal:  J Pharmacol Pharmacother       Date:  2013-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.